Surveillance for hepatocellular carcinoma: It is time to move forward.
作者信息
Kim Bo Hyun, Cho Yuri, Park Joong-Won
机构信息
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
出版信息
Clin Mol Hepatol. 2022 Oct;28(4):810-813. doi: 10.3350/cmh.2022.0257. Epub 2022 Sep 6.
Abstract
摘要
相似文献
1
Surveillance for hepatocellular carcinoma: It is time to move forward.肝细胞癌监测：是时候向前迈进了。
Clin Mol Hepatol. 2022 Oct;28(4):810-813. doi: 10.3350/cmh.2022.0257. Epub 2022 Sep 6.
2
Surveillance for hepatocellular carcinoma in patients with liver cirrhosis in India.印度肝硬化患者肝细胞癌的监测
Trop Gastroenterol. 2008 Oct-Dec;29(4):183-6.
3
Surveillance for hepatocellular carcinoma...a hotly debated issue.肝细胞癌的监测……一个备受争议的问题。
Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):255-64.
4
Surveillance of the patients at high risk for developing hepatocellular carcinoma in Europe--between guidelines and reality.欧洲肝细胞癌高危患者的监测——介于指南与现实之间。
Ultraschall Med. 2013 Oct;34(5):483-4. doi: 10.1055/s-0033-1346750.
5
Towards a New Horizon for Individualized Surveillance Tools in Hepatocellular Carcinoma.迈向肝细胞癌个体化监测工具的新视野
Clin Gastroenterol Hepatol. 2022 Jan;20(1):25-27. doi: 10.1016/j.cgh.2021.04.041. Epub 2021 Apr 30.
6
Hepatocellular carcinoma surveillance in patients with alcoholic cirrhosis.酒精性肝硬化患者的肝细胞癌监测
Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):651-3. doi: 10.1586/egh.12.59.
7
8
Serological surveillance for hepatocellular carcinoma: time to quit.肝细胞癌的血清学监测：是时候放弃了。
J Hepatol. 2010 Apr;52(4):614-5. doi: 10.1016/j.jhep.2009.11.026. Epub 2010 Jan 14.
9
Surveillance for hepatocellular carcinoma: how can we do better?肝细胞癌监测：我们如何做得更好？
Am J Med Sci. 2013 Oct;346(4):308-13. doi: 10.1097/MAJ.0b013e31828318ff.
10
Screening for hepatocellular carcinoma in cirrhosis.肝硬化患者肝细胞癌的筛查
J Hepatol. 2003 Dec;39(6):1076-84. doi: 10.1016/s0168-8278(03)00349-0.
引用本文的文献
1
METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.METTL1驱动的核苷酸代谢重编程肝细胞癌的免疫微环境：一种用于发现预后生物标志物的多组学方法
Front Immunol. 2025 Apr 22;16:1582203. doi: 10.3389/fimmu.2025.1582203. eCollection 2025.
2
Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area.定期甲胎蛋白检测提高了某流行地区肝细胞癌患者的治愈性治疗效果及生存率。
Cancers (Basel). 2023 Dec 28;16(1):150. doi: 10.3390/cancers16010150.
3
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap.台湾肝细胞癌的临床实践指南与实际临床应用：弥合差距
Clin Mol Hepatol. 2023 Apr;29(2):349-351. doi: 10.3350/cmh.2023.0082. Epub 2023 Mar 20.
4
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?为缩小韩国肝细胞癌指南与实际临床实践之间的差异，应采取哪些措施？
Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.
5
The prime time for management of hepatocellular carcinoma in Hong Kong.香港肝细胞癌的最佳治疗时机。
Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.
6
Correspondence on Editorial regarding "Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease".关于社论《全国肝细胞癌监测对慢性肝病患者预后的影响》的通信
Clin Mol Hepatol. 2023 Jan;29(1):182-184. doi: 10.3350/cmh.2022.0411. Epub 2022 Nov 22.
本文引用的文献
1
Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry.2012年至2014年韩国的肝细胞癌：基于韩国全国癌症登记数据的分析
J Liver Cancer. 2020 Sep;20(2):135-147. doi: 10.17998/jlc.20.2.135. Epub 2020 Sep 30.
2
Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry.韩国的肝细胞癌：对2015年韩国全国癌症登记处数据的分析
J Liver Cancer. 2021 Mar;21(1):58-68. doi: 10.17998/jlc.21.1.58. Epub 2021 Mar 31.
3
Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry.2008年至2011年韩国的肝细胞癌：基于韩国全国癌症登记处的分析
J Liver Cancer. 2020 Mar;20(1):41-52. doi: 10.17998/jlc.20.1.41. Epub 2020 Mar 31.
4
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.全国性肝细胞癌监测对慢性肝病患者预后的影响。
Clin Mol Hepatol. 2022 Oct;28(4):851-863. doi: 10.3350/cmh.2022.0037. Epub 2022 Jun 3.
5
Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.韩国乙型肝炎病毒相关性肝细胞癌患者生存率的提高：16 年队列变化。
PLoS One. 2022 Mar 24;17(3):e0265668. doi: 10.1371/journal.pone.0265668. eCollection 2022.
6
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.HCC 监测可提高肝硬化患者的早期检测、根治性治疗的获得和生存率：一项荟萃分析。
J Hepatol. 2022 Jul;77(1):128-139. doi: 10.1016/j.jhep.2022.01.023. Epub 2022 Feb 6.
7
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.慢性丙型肝炎治愈后伴晚期纤维化或肝硬化患者的 HCC 发病率：一项荟萃分析。
Hepatology. 2022 Jul;76(1):139-154. doi: 10.1002/hep.32341. Epub 2022 Feb 7.
8
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.乙型肝炎感染患者肝细胞癌的最佳预测模型。
Clin Mol Hepatol. 2022 Jul;28(3):351-361. doi: 10.3350/cmh.2021.0281. Epub 2021 Nov 26.
9
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.一种用于预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型。
J Hepatol. 2022 Feb;76(2):311-318. doi: 10.1016/j.jhep.2021.09.025. Epub 2021 Oct 2.
10
Hepatocellular carcinoma statistics in South Korea.韩国肝细胞癌统计数据。
Clin Mol Hepatol. 2021 Jul;27(3):512-514. doi: 10.3350/cmh.2021.0171. Epub 2021 Jun 21.
Zotero 插件